Captor Therapeutics Spolka Akcyjna Future Growth
Future criteria checks 5/6
Captor Therapeutics Spolka Akcyjna is forecast to grow earnings and revenue by 109.8% and 20.3% per annum respectively.
Key information
109.8%
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 31.8% |
| Revenue growth rate | 20.3% |
| Future return on equity | -92.2% |
| Analyst coverage | Low |
| Last updated | 09 Apr 2024 |
Recent future growth updates
Recent updates
We Think Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Drive Business Growth
Mar 10
We're Not Worried About Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn
Oct 03Here's Why We're Not At All Concerned With Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn Situation
Mar 13Companies Like Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Invest In Growth
Jun 15Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 78 | N/A | 6 | 20 | 1 |
| 12/31/2025 | 79 | 30 | -24 | 14 | 2 |
| 12/31/2024 | 53 | 6 | -52 | -14 | 2 |
| 12/31/2023 | 20 | -77 | -77 | -47 | 2 |
| 9/30/2023 | 13 | -66 | -40 | -37 | N/A |
| 6/30/2023 | 11 | -58 | -43 | -41 | N/A |
| 3/31/2023 | 10 | -39 | -26 | -25 | N/A |
| 12/31/2022 | 9 | -36 | -24 | -23 | N/A |
| 9/30/2022 | 5 | -40 | -32 | -26 | N/A |
| 6/30/2022 | 5 | -41 | -32 | -27 | N/A |
| 3/31/2022 | 5 | -38 | -29 | -24 | N/A |
| 12/31/2021 | 4 | -33 | -34 | -28 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CTX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.7%).
Earnings vs Market: CTX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CTX is expected to become profitable in the next 3 years.
Revenue vs Market: CTX's revenue (20.3% per year) is forecast to grow faster than the Polish market (4.3% per year).
High Growth Revenue: CTX's revenue (20.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CTX is forecast to be unprofitable in 3 years.